Colorectal Cancer

>

Latest News

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.
A2B530 Earns FDA Orphan Drug Designation in CEA+ Colorectal Cancer

March 6th 2024

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.

Panitumumab plus modified FOLFOX6 appears to increase survival among patients with metastatic colorectal cancer and circulating tumor DNA that has no gene alterations in the PARADIGM trial.
ctDNA-Based Negative Hyperselection May Guide Treatment Selection in mCRC

March 3rd 2024

The FDA has set a Prescription Drug User Fee Act date of June 21, 2024 for adagrasib plus cetuximab as a treatment for patients with previously treated KRAS G12C-mutated colorectal cancer.
FDA Grants Priority Review to Adagrasib Combo in KRAS G12C+ Advanced CRC

February 21st 2024

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.
Cancer Vaccine Shows Efficacy and Safety Potential in PDAC and CRC

February 13th 2024

Results from part 3 of the phase 2a CORIST trial found that combining SCO-101 with chemotherapy improved the progression-free survival and clinical benefit rate in patients with metastatic colorectal cancer.
Novel Drug Shows Increased Efficacy in Small Metastatic CRC Population

February 6th 2024

Video Series
Video Interviews
Podcasts
New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
New treatment updates could help find more patient subtypes to target and treat in the world of CRC.
Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.
Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.
Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal Cancer
Oncology Peer Review On-The-Go
Oncology Peer Review On-The-Go

More News